Stay updated on ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial page.

Latest updates to the ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page shows a redesigned layout and updated visuals for the Study Details page, but no study data or eligibility content appears to have changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check20 days agoNo Change Detected
- Check41 days agoChange DetectedAdded a government-status notice and a v3.2.0 revision; removed the v3.1.0 revision. The page now informs users about potential delays and where to check current operating status, and indicates the new version.SummaryDifference6%

- Check48 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

- Check62 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2; the 'Back to Top' link was removed.SummaryDifference0.3%

- Check70 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content or other important factors.SummaryDifference0.3%

- Check77 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, as well as updated drug information for Acalabrutinib and Pembrolizumab. However, several key details, such as specific location terms and previous drug information, have been removed.SummaryDifference4%

Stay in the know with updates to ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ACP-196 and Pembrolizumab in Pancreatic Cancer Clinical Trial page.